Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03067441 · ClinicalTrials.gov registry record · Phase 3
Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)
A Phase 3 study, sponsored by Esperion Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,462
- Enrollment target
NCT03067441: Completed Phase 3 study, sponsored by Esperion Therapeutics.
NCT03067441 is a Phase 3 study that has completed, run by Esperion Therapeutics. The registered enrollment target is 1,462 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (89% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03067441, a Phase 3 study, has completed, sponsored by Esperion Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,462 participants
- Enrollment target
Study Summary
The purpose of this study is to see if bempedoic acid (ETC-1002) is safe and well-tolerated in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.
Primary Outcome
TEAEs are defined as adverse events that began or worsened in severity after the first dose of investigational medicinal product (IMP) until 30 days after the last dose in the Open-Label Extension (OLE) Study.
Interventions
- DRUG bempedoic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,462 participants |
| Start Date | 2017-02-03 |
| Est. Completion | 2019-11-05 |
| Phase | Phase 3 |
What the finished NCT03067441 record still lists
NCT03067441 is an interventional study that assigns participants to a tested intervention. Its 1,462 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (89% higher).
The record links to 0 conditions, and to 1 intervention - of which bempedoic acid is the first listed.
NCT03067441 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03067441 about?
NCT03067441 is a clinical study titled "Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)". The purpose of this study is to see if bempedoic acid (ETC-1002) is safe and well-tolerated in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.
What is the current status of trial NCT03067441?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,462 participants. The study started on 2017-02-03. Estimated completion is 2019-11-05.
What interventions are being tested in trial NCT03067441?
The interventions under investigation include: bempedoic acid (DRUG).
Who is sponsoring clinical trial NCT03067441?
This trial is sponsored by Esperion Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03067441's enrollment target sits among peer trials
1,462 164th of 2000 higher than 1,837 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03936361 · 1,456 participants · Phase 3
Statins In Intracerbral Hemorrhage
- NCT06782347 · 1,454 participants · NA
Activating SilverSneakers Benefits for Seniors With Osteoarthritis
- NCT04566328 · 1,450 participants · Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- NCT05229341 · 1,450 participants · NA
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI